Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 7/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 9/20 | 0.43 |
| ▸ | YES1 | P07947 | 5/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 2/20 | 0.42 |
| ▸ | CIT | O14578 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15301493 | 0.85 | GALR2 (0.40) | ABL1HRH3BCRMCHR1 | |
| SCHEMBL9942806 | 0.84 | HRH3 (0.45) | AXLKDREPHB4EPHA2ABL1 | |
| SCHEMBL9943213 | 0.81 | KDM4E (0.42) | KDREPHB4EPHA2KCNH2EGFR | |
| SCHEMBL29498285 | 0.80 | NTRK1 (0.49) | KDRABL1KCNH2EGFRHRH3 | |
| SCHEMBL17443160 | 0.80 | NTRK1 (0.49) | KDRABL1KCNH2EGFRHRH3 | |
| SCHEMBL9939330 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2 | |
| SCHEMBL9938896 | 0.78 | SMN1; SMN2 (0.47) | AXLKDREPHB4EPHA2EGFR | |
| SCHEMBL20124518 | 0.78 | SMN1; SMN2 (0.43) | KDREPHB4EPHA2ABL1EGFR | |
| SCHEMBL9943627 | 0.77 | NTRK1 (0.47) | AXLKDREPHB4EPHA2ABL1 | |
| SCHEMBL17434796 | 0.76 | ABL1 (0.52) | ABL1BCRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651416-B1 | COMPOUNDS USEFUL FOR TREATING AIDS | ABIVAX (FR) | 2018-05-09 | — | — | EP | claimed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | claimed |
| WO-2023139233-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-27 | — | — | WO | disclosed |
| EP-4215196-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023135207-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4212156-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-19 | — | — | EP | disclosed |
| US-20220145406-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | ABIVAX (FR) | 2022-05-12 | — | — | US | disclosed |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2022-01-27 | — | — | US | disclosed |
| WO-2020127843-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127853-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | ABIVAX (FR) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127839-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF CANCER | ABIVAX (FR) | 2020-06-25 | — | — | WO | disclosed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | disclosed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | disclosed |
| EP-2651416-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | Splicos (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080953-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2012-06-21 | — | — | WO | disclosed |
| EP-2465502-A1 | Compounds useful for treating AIDS | Société Splicos (FR) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465502-A1 | Compounds useful for treating AIDS | Société Splicos (FR) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR3, CBR1, CCR10 | AXL 1324/4885KDR 3471/4885EPHB4 2323/4885 |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | NR1H3, NR1H2, NR1H4 | AXL 2285/4885KDR 2235/4885EPHB4 1781/4885 |
| US-20220145406-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | HAVCR2, CXCL8, IL36G | AXL 2485/4885KDR 1114/4885EPHB4 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.